Angle's 'Parsortix' used in new groundbreaking cancer research
11th Feb 2019 11:35
(Sharecast News) - Liquid biopsy company Angle announced on Monday that its 'Parsortix' system had been utilised in further "groundbreaking" cancer research into CTC clusters, reportedly demonstrating that the patient's own immune cells (neutrophils) could actively help the process of metastasis by which the cancer spread.
Read moreAngle sees 'highly encouraging' results from prenatal testing
29th Oct 2018 11:08
(Sharecast News) - Medical diagnostics outfit Angle is talking to "several interested parties" to commercialise its testing device after a "highly encouraging" trial indicated it could be adapted as a non-invasive prenatal test.
Read moreAngle makes 'good progress' with ANG-002 patient enrolment
25th Oct 2018 08:52
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that patient enrolment for its ANG-002 FDA clinical study for metastatic breast cancer had continued to make good progress.
Read moreAngle selected for European cancer ID programme
13th Feb 2017 08:55
(ShareCast News) - Medical technology company Angle has been chosen to take part in Cancer-ID, a European consortium to validate blood-based biomarkers for cancer, by providing a number of Parsortix instruments and associated consumables for evaluation. The evaluation phase, which runs until 2020, w
Read moreAngle initiates 200 patient European ovarian cancer study
19th Jul 2016 12:56
(ShareCast News) - Medical technology company Angle's European ovarian cancer study has been formally initiated with a first patient recruited. Angle completed the process required to initiate this study, which included optimising the system protocols for the application, development and approval of
Read moreSunday share tips: Purplebricks, Associated British Foods, Angle
12th Jun 2016 13:28
(ShareCast News) - Purplebricks Group shares were a 'buy' in the Sunday Times' Inside the City column. Investing in this online estate agency might be a wild ride, with the shares trading for more than 40 times earnings, but some notable names are on the register since its IPO at the end of last yea
Read moreAngle closer to using cassette tech for prostate cancer detection
21st Mar 2016 14:04
(ShareCast News) - There was praise for the progress made by Angle on Monday, in its quest to see one of its existing products used as a diagnostic tool for prostate cancer. The AIM-traded company was the subject of a report by equity advisory firm Edison, which said that while the final data was ye
Read moreAngle posts positive prostate cancer treatment tests update
11th Jun 2015 11:39
Medical diagnostic company Angle said the investigation into the clinical use of its Parsortix system in prostate cancer treatments was encouraging. Researchers from Barts Cancer Institute, which is carrying out the tests, were able to successfully harvest circulating tumor cells from all the 52 ass
Read moreAngle to collaborate with USC Norris on breast cancer treatment
19th Sep 2014 08:28
AIM-listed medtech group Angle has signed a collaboration agreement with the University of Southern California (USC) Norris Comprehensive Cancer Center to investigate the clinical use of the Parsortix system for breast cancer. The collaboration follows four months of evaluation by USC Norris of Angl
Read moreAngle wins EU authorisation for Parsortix
17th Dec 2013 11:53
Medical diagnostic device maker Angle has won European approval for a system used in the diagnosis and treatment of cancer patients. Angle said regulators had authorized its Parsortix cell separation system for use as an in-vitro diagnostic device in the EU. The system uses blood analysis to diagn
Read moreANGLE sells Geomerics business to ARM Holdings
13th Dec 2013 11:41
Specialist medtech company ANGLE has raised 6.2m pounds after realising its investment in graphics technology developer Geomerics, which it sold to ARM Holdings. The group said the additional financial resources will be used within its Parsortix non-invasive cancer diagnostics business, enabling i
Read moreAngle shares jump on cell harvesting update
13th May 2013 14:34
Shares in Angle, a specialist medtech company, leapt 20 per cent on Monday after the group said it has extended the operational capability of its Parsortix non-invasive cancer diagnostic product by automating its cell harvesting function. Harvesting is where captured tumour cells are recovered from
Read moreAngle initiates launch of cancer diagnostic product for market research
28th Feb 2013 13:36
Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market. The product is based on taking a blood test, and the system either counts circulating tumour cells (CTCs) in the blood or captures and recovers
Read moreAngle raises funds with placing
31st Jan 2013 13:13
Angle, a specialist medtech company, has placed 4.53m new ordinary shares at 50p each, representing a discount of 17.4 per cent on the mid-price of 60.50p per share at close of business on Wednesday. Net of costs, the placing raised £2.2m, which will be used to strengthen the company's financial p
Read moreAngle jumps again after pay out
15th Jan 2013 08:47
Medical technology firm Angle saw its shares jump for a second day in a row after it received cash due from the sale of its portfolio company Acoylte Biomedica. The 2007 sale led to a legal case over an earn-out provision, which saw former Acolyte shareholder, Porton Capital, take the buyer, 3M, to
Read more